Valbiotis announces the first international scientific communication of the data from the Phase II HEART clinical study with TOTUM•070 against hypercholesterolemia. These positive results were selected by the 91st Congress of the European Atherosclerosis Society (EAS), one of the major events in the cardiovascular field in Europe, which is being held this year in Mannheim (Germany) from 21 to 24 May, 2023. The HEART study is the subject of a dedicated presentation during the Science at a Glance oral sessions on 22 and 23 May.
In addition, Valbiotis also presents the latest preclinical data on intestinal lipid absorption with TOTUM•070. See posters